BioCryst Ebola drug BCX4430 enters safety testing
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals' experimental Ebola drug BCX4430, a nucleoside RNA polymerase inhibitor, has entered a Phase I trial in healthy subjects testing the safety, tolerability and pharmacokinetics of escalating doses administered via intramuscularly.